9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma, Malignant

Estimated Enrollment: 120

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Disease control rate (DCR) at 12 weeks assessed by modified RECIST 1.1, in patients with relapsed mesothelioma.,  Disease control rate (DCR) at 24 weeks assessed by modified RECIST 1.1, in patients with relapsed mesothelioma.,  Objective response rate (ORR) assessed for 12 months, Safety assessed according to CTCAE criteria.

Interventions: Rucaparib, Abemaciclib

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: July 30, 2021

Completion Date: November 30, 2021

Last  Posted Date: February 1, 2019

Location: University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Website Link: https://ClinicalTrials.gov/show/NCT03654833

Was this article helpful?
Dislike 0